The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Primary efficacy analyses of NeoRHEA, neoadjuvant biomarker research study of palbociclib combined with endocrine therapy in estrogen receptor positive/HER2 negative breast cancer.
 
Elisa Agostinetto
Honoraria - AstraZeneca; Lilly; Sandoz
Research Funding - Gilead Sciences (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo Europe GmbH; Genetic Spa; Novartis
 
Andreas Papagiannis
No Relationships to Disclose
 
Frederic Cailleux
No Relationships to Disclose
 
Mariana Brandão
Speakers' Bureau - Janssen (Inst); Roche/Genentech
Research Funding - AstraZeneca (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Sanofi; Takeda
 
Alexandra Stanciu
No Relationships to Disclose
 
Denis Larsimont
No Relationships to Disclose
 
Isabelle Veys
No Relationships to Disclose
 
Marianne Paesmans
No Relationships to Disclose
 
Tatiana Besse-Hammer
No Relationships to Disclose
 
Ahmad Awada
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Lilly; Eisai; Genomic Health; Hengrui Therapeutics; Innate Pharma; Ipsen; LEO Pharma; Lilly; Merck Serono; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
 
Martine J. Piccart-Gebhart
Consulting or Advisory Role - AstraZeneca; Camel-IDS; Frame Therapeutics; Gilead Sciences; Immunomedics; Immutep; Lilly; Menarini; MSD; NBE Therapeutics; Novartis; Pfizer; Roche/Genentech; Seagen; Seagen
Research Funding - AstraZeneca (Inst); Immunomedics/Gilead (Inst); Lilly (Inst); Menarini (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Roche/Genentech (Inst); Servier (Inst); Synthon (Inst)
Other Relationship - Oncolytics
 
Christos Sotiriou
Consulting or Advisory Role - Amgen; Amgen; Astellas Pharma; Astellas Pharma; CEPHEID; Merck; Puma Biotechnology; Seagen; Vertex
Speakers' Bureau - Eisai; Foundation Medicine; Genomic Health; Prime Oncology; Teva
Patents, Royalties, Other Intellectual Property - A companion diagnostic for CDK4/CDK6 inhibitory drugs based on CDK4 Phosphorylation. Which patient to be treated and how. PCT/EP2017/061780; Epigenetic portraits of human Breast Cancer, PCT/EP2012/050836, WO2012/098215
Travel, Accommodations, Expenses - Roche; Roche/Genentech; Roche/Genentech
 
Lieveke Ameye
No Relationships to Disclose
 
Patrick Neven
Consulting or Advisory Role - Lilly (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Radius Health (Inst); Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Lilly (Inst); Pfizer (Inst); Roche (Inst)
 
Francois P. Duhoux
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Amgen; Daiichi Sankyo/Astra Zeneca; Pfizer; Roche; Teva
 
Peter Vuylsteke
Honoraria - MSD Oncology; Novartis; Roche/Genentech
Travel, Accommodations, Expenses - Roche
 
Michail Ignatiadis
Consulting or Advisory Role - Seagen
Speakers' Bureau - Novartis
Research Funding - Inivata (Inst); Natera (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Patent entitled method for determining sensitivity to a CDK4/6 inh filed the 18 05 16 by Universite Libre de Bruxelles, Application No/Patent No 16170146.1-1403
Travel, Accommodations, Expenses - Gilead Sciences (Inst); Roche (Inst)